학술논문

Clinical descriptive analysis of severe Pneumocystis jirovecii pneumonia in renal transplantation recipients
Document Type
article
Source
Bioengineered, Vol 12, Iss 1, Pp 1264-1272 (2021)
Subject
metagenomic next-generation sequencing (mngs)
pneumocystis jirovecii pneumonia (pjp)
renal transplantation
opportunistic fungal infection
trimethoprim-sulfamethoxazole (tmp-smx)
Biotechnology
TP248.13-248.65
Language
English
ISSN
2165-5979
2165-5987
21655979
Abstract
Pneumocystis jirovecii (P. jirovecii) pneumonia (PJP) is an opportunistic fungal infection after renal transplantation, which is always severe, difficult to diagnose, combined with multiple complications and have poor prognosis. We retrospectively analyzed clinical data, including risk factors, diagnosis, treatment and complications of seven clinical cases suffered with severe PJP after renal transplantation in our department in 2019. All the seven recipients were routinely prescribed with PJP prophylaxis after renal transplantation, and six of them suffered acute graft rejection before the infection. P. jirovecii sequence was identified in blood or broncho-alveolar lavage fluid (BALF) by the metagenomic next-generation sequencing (mNGS) in all patients. All the patients were improved with the therapy trimethoprim-sulfamethoxazole (TMP-SMX) combined with caspofungin for the PJP treatment, but suffered with complications including renal insufficiency, leukopenia, thrombocytopenia, gastrointestinal bleeding, mediastinalemphysema, pulmonary hemorrhage, and hemophagocytic syndrome and other severe infections. Taken together, mNGS is a powerful tool that could be used to diagnose PJP in renal transplantation recipients. And PJP prophylaxis should be prescribed during and after treatment for acute rejection. TMP-SMX is the first-line and effective drug for PJP treatment, but the complications are always life-threatening and lead to poor prognosis. We should pay attention to these life-threatening complications.